Edge Medical’s Successful HKEX Main Board Listing

Cleary Gottlieb acted as Hong Kong and U.S. legal counsel of the issuer for the global offering of Shenzhen Edge Medical Co. Ltd. (Edge Medical)(2675.HK), which has successfully listed on the Main Board of the Hong Kong Stock Exchange on January 8, 2026.

The offering comprised 27,722,200 H shares at an offer price of HK$43.24 per H share, raising approximately HK$1.12 billion (excluding the over-allotment option).

Innovative Structure and Regulatory Excellence

The transaction adopted an international offering structure in compliance with Regulation S and Rule 144A under the U.S. Securities Act. Cleary leveraged its deep experience in Hong Kong and U.S. capital markets to advise on offering structure, cross-border compliance, and application of U.S. securities law, ensuring seamless execution and optimal balance between compliance and market acceptance.

Underwriters and Cornerstone Investors

The underwriting syndicate included Morgan Stanley Asia Limited and GF Capital (Hong Kong) Limited as joint sponsors, joint overall coordinators, joint global coordinators, joint bookrunners, and joint lead managers, alongside other leading international and local investment banks. The offering attracted cornerstone investments from prominent institutions, including Abu Dhabi Investment Authority, UBS Asset Management, OrbiMed, Tencent, and LYFE Capital, underscoring strong global investors’ confidence in Edge Medical.

Industry Significance and Highlights

This transaction marks a major milestone for the medical technology sector and reflects capital markets’ strong recognition of innovative medical devices. Edge Medical is the first company in China to obtain regulatory approvals for multi-port, single-port, and natural orifice surgical robots, positioning itself as a global leader in surgical robotics and making this one of the most anticipated healthcare IPOs on HKEX in 2026.

Cleary’s Role

Cleary remains committed to delivering high-quality, tailored legal solutions to global capital market participants, supporting issuers and underwriters with professionalism and efficiency throughout complex cross-border transactions.

The Cleary team was led by partners Freeman Chan, Shuang Zhao, Miao Zhang, and Biyuan Zhang, and included counsel Robert Williams and associates Beverly Lam, Taoran Wang, Lei Zhang, Winston Ma, and Martin Wong.